Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shijiazhuang Pharmaceutical Group Receives EDQM Certification For Vitamin B12

This article was originally published in PharmAsia News

Executive Summary

Shijiazhuang Pharmaceutical Group has gained an on-site inspection certification for its vitamin B12 from the European Directorate for the Quality of Medicines, making it the first in China's vitamin B12 industry. The endorsement will allow China-made vitamin B12 to enter the high-end pharmaceutical field in 34 countries for manufacturing and sale. The potential market expansion and economic benefit represents major progress for local products which hitherto got little profit from the feedstuff and food industry. To avoid vicious competition in the low-end market, Shijiazhuang Pharmaceutical recently stepped up its international certification and registration efforts; it has already received EU Certificate of Suitability for six products - vitamin C, vitamin B12, caffeine, ranitidine, theophylline and amoxicillin. (Click her for more - Chinese Language)

You may also be interested in...

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts